Literature DB >> 18940577

Immunoglobulin replacement therapy in children.

Maria Garcia-Lloret1, Sean McGhee, Talal A Chatila.   

Abstract

The benefit of immunoglobulin (IG) replacement in primary antibody deficiencies is unquestionable. Many of these congenital disorders present early in life and this therapy is often first implemented in the young. This article focuses on the indications of IG replacement in children, with an emphasis on the specific diagnostic problems encountered in this population. Also presented is an overview of the practical aspects of IG administration in the pediatric setting, including the recognition and management of adverse reactions. Finally, the advent of subcutaneous IG, a therapeutic IG modality with the potential to have a great impact on the quality of life of children with antibody deficiencies and their families, is discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18940577      PMCID: PMC2585601          DOI: 10.1016/j.iac.2008.07.001

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  98 in total

Review 1.  Molecular basis of IgG subclass deficiency.

Authors:  Q Pan; L Hammarström
Journal:  Immunol Rev       Date:  2000-12       Impact factor: 12.988

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

4.  An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum.

Authors:  F Lamari; E D Anastassiou; T Tsegenidis; G Dimitracopoulos; N K Karamanos
Journal:  J Pharm Biomed Anal       Date:  1999-09       Impact factor: 3.935

5.  IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy.

Authors:  R de Albuquerque Campos; M N Sato; A J da Silva Duarte
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

6.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

7.  Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women.

Authors:  A Gardulf; E Andersson; M Lindqvist; S Hansen; R Gustafson
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

8.  Serum levels of immunoglobulins and IgG subclasses in steroid sensitive nephrotic syndrome.

Authors:  Markus J Kemper; Hans Altrogge; Rainer Ganschow; Dirk E Müller-Wiefel
Journal:  Pediatr Nephrol       Date:  2002-06       Impact factor: 3.714

9.  Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.

Authors:  Paula Jane Busse; Samiya Razvi; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2002-06       Impact factor: 10.793

Review 10.  Immunoglobulin G subclass deficiency: fact or fancy?

Authors:  Rebecca H Buckley
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.919

View more
  9 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

Review 2.  Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.

Authors:  Vincent R Bonagura
Journal:  J Clin Immunol       Date:  2012-12-28       Impact factor: 8.317

Review 3.  Common variable immunodeficiency: etiological and treatment issues.

Authors:  Sean Deane; Carlo Selmi; Stanley M Naguwa; Suzanne S Teuber; M Eric Gershwin
Journal:  Int Arch Allergy Immunol       Date:  2009-07-01       Impact factor: 2.749

Review 4.  Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

Authors:  Helena Edlund; Johanna Melin; Zinnia P Parra-Guillen; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 5.577

5.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017

Review 6.  Specific Antibody Deficiency: Controversies in Diagnosis and Management.

Authors:  Elena Perez; Francisco A Bonilla; Jordan S Orange; Mark Ballow
Journal:  Front Immunol       Date:  2017-05-22       Impact factor: 7.561

7.  M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

Authors:  Leona E Ling; Jan L Hillson; Renger G Tiessen; Tjerk Bosje; Mattheus Paulus van Iersel; Darrell J Nix; Lynn Markowitz; Nicholas A Cilfone; Jay Duffner; James B Streisand; Anthony M Manning; Santiago Arroyo
Journal:  Clin Pharmacol Ther       Date:  2018-12-04       Impact factor: 6.875

8.  Hypogammaglobulinemia due to CAR T-cell therapy.

Authors:  Andrew Doan; Michael A Pulsipher
Journal:  Pediatr Blood Cancer       Date:  2017-12-12       Impact factor: 3.167

9.  One-year intravenous immunoglobulin replacement therapy: efficacy in reducing hospital admissions in pediatric patients with Inborn Errors of Immunity.

Authors:  Karina Mescouto de Melo; Lucas Macedo Alves; Cláudia França Cavalcante Valente; Fabíola Scancetti Tavares
Journal:  J Pediatr (Rio J)       Date:  2021-07-14       Impact factor: 2.990

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.